CRISPR Therapeutics (CRSP) P/E ratio
Only 2 fiscal years of P/E ratio are on record here for CRISPR Therapeutics (CRSP); a history needs at least 3. Figures as of 18 Nov 2026, 09:53 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio, fiscal 2021
- 16.1×
- Fiscal years on record
- 22019–2021
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/E ratio needs at least 3 fiscal years; 2 are on record here for CRISPR Therapeutics. Nothing is estimated to fill the gap. What is on record is in the table below.
CRISPR Therapeutics P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | $52.44 | -$6.47 | |
| 2024 | — | — | $39.36 | -$4.34 | |
| 2023 | — | — | $62.60 | -$1.94 | |
| 2022 | — | — | $40.65 | -$8.36 | |
| 2021 | 16.1× | — | $75.78 | $4.70 | |
| 2020 | — | — | $153.11 | -$5.29 | |
| 2019 | 52.1× | — | $60.90 | $1.17 | |
| 2018 | — | — | $28.57 | -$3.44 | |
| 2017 | — | — | $23.48 | -$1.71 | |
| 2016 | — | — | $20.26 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Heartflow HTFL | 70.3× |
| Option Care Health OPCH | 22.9× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
CRISPR Therapeutics, figure by figure
- CRISPR Therapeutics market cap
- CRISPR Therapeutics revenue
- CRISPR Therapeutics earnings
- CRISPR Therapeutics earnings per share (EPS)
- CRISPR Therapeutics P/S ratio
- CRISPR Therapeutics P/B ratio
- CRISPR Therapeutics free cash flow
- CRISPR Therapeutics operating margin
- CRISPR Therapeutics dividend
- CRISPR Therapeutics shares outstanding
- CRISPR Therapeutics total debt
- CRISPR Therapeutics cash on hand
- CRISPR Therapeutics total assets
- CRISPR Therapeutics return on equity (ROE)
- CRISPR Therapeutics return on invested capital (ROIC)
CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value
CRISPR Therapeutics P/E ratio: questions and answers
How is CRISPR Therapeutics's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For CRISPR Therapeutics it is on record here for 2 fiscal years, 2019 to 2021.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “CRISPR Therapeutics (CRSP) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CRSP/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.